Back

Pharma Equity Group faces challenge to €10.5 million arbitral award

Verifying
  • Interpatium commenced proceedings seeking to set aside Pharma Equity Group’s arbitral award.
  • EUR 10.5 million plus interest and costs is owed to PEG under the award.
  • Pharma Equity Group will continue enforcement because the proceedings do not automatically suspend the award.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.